
Seres Therapeutics Investor Relations Material
Latest events

Q1 2025
Seres Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Seres Therapeutics Inc
Access all reports
Seres Therapeutics, Inc. is a microbiome therapeutics platform company that engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate which has completed Phase III clinical trial for the treatment of CDI. It also develops SER-155 and SER-287 which are in Phase Ib clinical trial to reduce incidences of gastrointestinal infections and ulcerative colitis; SER-301 that is in Phase Ib clinical trial to treat metastatic melanoma; and SER-262 to treat Clostridioides difficile infection.
Key slides for Seres Therapeutics Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Seres Therapeutics Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Seres Therapeutics Inc
Latest articles
)
Nintendo: From Game Boy and Pokémon to Switch 2 and Mario Kart
Nintendo went from card maker to cultural icon, shaping modern entertainment through hardware innovation and world-famous characters.
19 Jun 2025
)
Ron Vachris: From Forklift Driver to CEO at Costco
Ron Vachris took over as Costco CEO in 2024, following a 40-year journey from warehouse floors to the top of one of retail's most admired companies.
18 Jun 2025
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
Ticker symbol
MCRB
Country
🇺🇸 United States